

## Genetic Pharmacology Services Report References

### Psychiatry Pharmacogenetics Expanded Panel<sup>1-18</sup>

1. Bråten LS, Haslemo T, Jukic MM, Ingelman-Sundberg M, Molden E, Kringen MK. Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients. *Neuropsychopharmacology*. 2020;45(3):570-576. doi:10.1038/s41386-019-0554-x
2. Brown JT, Abdel-Rahman SM, Van Haandel L, Gaedigk A, Lin YS, Leeder JS. Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD. *Clin Pharmacol Ther*. 2016;99(6):642-650. doi:10.1002/cpt.319
3. Hicks JK, Swen JJ, Thorn CF, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. *Clin Pharmacol Ther*. 2013;93(5):402-408. doi:10.1038/clpt.2013.2
4. Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. *Clin Pharmacol Ther*. 2015;98(2):127-134. doi:10.1002/cpt.147
5. Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. *Clin Pharmacol Ther*. 2017;102(1):37-44. doi:10.1002/cpt.597
6. Jukić MM, Haslemo T, Molden E, Ingelman-Sundberg M. Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: A retrospective study based on 2,087 patients. *Am J Psychiatry*. 2018;175(5):463-470. doi:10.1176/appi.ajp.2017.17050550
7. Mrazek DA, Lerman C. Facilitating Clinical Implementation of Pharmacogenomics. 2011;306(3):304-305.
8. Pratt VM, Del Tredici AL, Hachad H, et al. Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A Report of the Association for Molecular Pathology. *J Mol Diagnostics*. 2018;20(3):269-276. doi:10.1016/j.jmoldx.2018.01.011
9. Stingl JC, Brockmüller J, Viviani R. Genetic variability of drug-metabolizing enzymes: The dual impact on psychiatric therapy and regulation of brain function. *Mol Psychiatry*. 2013;18(3):273-287. doi:10.1038/mp.2012.42
10. Botton MR, Whirl-Carrillo M, Del Tredici AL, et al. PharmVar GeneFocus: CYP2C19. *Clin Pharmacol Ther*. 2021;109(2):352-366. doi:10.1002/cpt.1973
11. Brown JT, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy. *Clin Pharmacol Ther*. 2019;106(1):94-102. doi:10.1002/cpt.1409
12. Caudle KE, Sangkuhl K, Whirl-Carrillo M, et al. Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. *Clin Transl Sci*. 2020;13(1):116-124. doi:10.1111/cts.12692
13. CDER FDA. HIGHLIGHTS OF PRESCRIBING INFORMATION for ABILIFY. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2014/021436s038,021713s030,021729s022,021866s023lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021436s038,021713s030,021729s022,021866s023lbl.pdf). Published 2014. Accessed March 16, 2020.
14. Chang M, Tybring G, Dahl ML, Lindh JD. Impact of Cytochrome P450 2C19 Polymorphisms on Citalopram/Escitalopram Exposure: A Systematic Review and Meta-Analysis. *Clin Pharmacokinet*. 2014;53(9):801-811. doi:10.1007/s40262-014-0162-1
15. DailyMed - ATOMOXETINE- atomoxetine hydrochloride capsule. <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48980c85-2fa0-4c9e-b182-227b0d057f6b>. Accessed May 28, 2020.

## Genetic Pharmacology Services Report References

16. DailyMed - THIORIDAZINE HYDROCHLORIDE tablet, film coated. <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56b3f4c2-52af-4947-b225-6808ae9f26f5>. Accessed May 28, 2020.
17. Falzoi M, Mossa A, Congeddu E, Saba L, Pani L. Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF mass spectrometry. *Pharmacogenomics*. 2010;11(4):559-571. doi:10.2217/pgs.09.172
18. Falzoi M, Pira L, Lazzari P, Pani L. Genotyping of CYP2D6 Polymorphisms by MALDI-TOF Mass Spectrometry in Sardinian People. *ISRN Genet*. 2013:609797. doi:10.5402/2013/609797

### CYP2D6 Opioid Panel<sup>1-9</sup>

1. Falzoi M, Mossa A, Congeddu E, Saba L, Pani L. Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF mass spectrometry. *Pharmacogenomics*. 2010;11(4):559-571. doi:10.2217/pgs.09.172
2. Falzoi M, Pira L, Lazzari P, Pani L. Genotyping of CYP2D6 Polymorphisms by MALDI-TOF Mass Spectrometry in Sardinian People. *ISRN Genet*. 2013:609797. doi:10.5402/2013/609797
3. Nofziger C, Turner AJ, Sangkuhl K, et al. PharmVar GeneFocus: CYP2D6. *Clin Pharmacol Ther*. 2020;107(1):154-170. doi:10.1002/cpt.1643
4. Crews KR, Caudle KE, Dunnenberger HM, Sadhasivam S, Skaar TC. Considerations for the utility of the CPIC guideline for CYP2D6 genotype and codeine therapy. *Clin Chem*. 2015. doi:10.1373/clinchem.2014.237412
5. Caudle KE, Sangkuhl K, Whirl-Carrillo M, et al. Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. *Clin Transl Sci*. 2020;13(1):116-124. doi:10.1111/cts.12692
6. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 Update. *Clin Pharmacol Ther*. 2014. doi:10.1038/clpt.2013.254
7. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. *Clin Pharmacol Ther*. 2012;91(2):321-326. doi:10.1038/clpt.2011.287
8. FDA (Food and Drug Administration). *Safety Review Update of Codeine Use in Children; New Boxed Warning and Contraindication on Use after Tonsillectomy and/or Adenoidectomy*. <https://www.fda.gov/media/85072/download>. Accessed March 31, 2020.
9. Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 , OPRM1 , and COMT genotype and select opioid therapy . *Clin Pharmacol Ther*. January 2021. doi:10.1002/cpt.2149

### CYP2D6/2C19 Genotype Analysis<sup>1-5</sup>

1. Falzoi M, Mossa A, Congeddu E, Saba L, Pani L. Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF mass spectrometry. *Pharmacogenomics*. 2010;11(4):559-571. doi:10.2217/pgs.09.172
2. Falzoi M, Pira L, Lazzari P, Pani L. Genotyping of CYP2D6 Polymorphisms by MALDI-TOF Mass Spectrometry in Sardinian People. *ISRN Genet*. 2013:609797. doi:10.5402/2013/609797
3. Nofziger C, Turner AJ, Sangkuhl K, et al. PharmVar GeneFocus: CYP2D6. *Clin Pharmacol Ther*. 2020;107(1):154-170. doi:10.1002/cpt.1643

## Genetic Pharmacology Services Report References

4. Botton MR, Whirl-Carrillo M, Del Tredici AL, et al. PharmVar GeneFocus: CYP2C19. *Clin Pharmacol Ther.* 2021;109(2):352-366. doi:10.1002/cpt.1973
5. Caudle KE, Sangkuhl K, Whirl-Carrillo M, et al. Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. *Clin Transl Sci.* 2020;13(1):116-124. doi:10.1111/cts.12692

### CYP3A5 Genotype Analysis (tacrolimus)<sup>1-8</sup>

1. Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. *Clin Pharmacol Ther.* 2015;98(1):19-24. doi:10.1002/cpt.113
2. Brunet M, van Gelder T, Åsberg A, et al. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy. *Ther Drug Monit.* 2019;41(3):261-307. doi:10.1097/FTD.0000000000000640
3. Elens L, Capron A, Van Schaik R, et al. Impact of CYP3A4\*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: Toward updated genotype-based dosage guidelines. *Ther Drug Monit.* 2013;35(5):608-616. doi:http://dx.doi.org/10.1097/FTD.0b013e318296045b
4. Hooper DK, Fukuda T, Gardiner R, et al. Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation. *Transplantation.* 2012;93(8):806-812. doi:10.1097/TP.0b013e318247a6c7
5. Hooper DK, Carle AC, Schuchter J, Goebel J. Interaction between tacrolimus and intravenous nicardipine in the treatment of post-kidney transplant hypertension at pediatric hospitals. *Pediatr Transplant.* 2011;15(1):88-95. doi:10.1111/j.1399-3046.2010.01417.x
6. Tang JT, Andrews LM, van Gelder T, et al. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. *Expert Opin Drug Metab Toxicol.* 2016;12(5):555-565. doi:10.1517/17425255.2016.1170808
7. Min S, Papaz T, Lafreniere-Roula M, et al. A randomized clinical trial of age and genotype-guided tacrolimus dosing after pediatric solid organ transplantation. *Pediatr Transplant.* 2018;22(7):1-9. doi:10.1111/petr.13285
8. Saint-Marcoux F, Woillard J-B, Jurado C, Marquet P. Lessons From Routine Dose Adjustment of Tacrolimus in Renal Transplant Patients Based on Global Exposure. *Ther Drug Monit.* 2013;35(3):322-327. doi:10.1097/FTD.0b013e318285e779

### TPMT Genotype Analysis<sup>1-4</sup>

1. Relling M V., Pui CH, Cheng C, Evans WE. Thiopurine methyltransferase in acute lymphoblastic leukemia. *Blood.* 2006;107(2):843-844. doi:10.1182/blood-2005-08-3379
2. Relling M V., Gardner EE, Sandborn WJ, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. *Clin Pharmacol Ther.* 2011;89(3):387-391. doi:10.1038/clpt.2010.320

## Genetic Pharmacology Services Report References

3. Relling M V., Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. *Clin Pharmacol Ther.* 2019;105(5):1095-1105. doi:10.1002/cpt.1304
4. Crandall W V., Margolis PA, Kappelman MD, et al. Improved outcomes in a quality improvement collaborative for pediatric inflammatory bowel disease. *Pediatrics.* 2012;129(4). doi:10.1542/peds.2011-1700

### Warfarin Pharmacogenetics <sup>1-5</sup>

1. Falzoi M., Mossa, A., et al. (2010). Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF mass spectrometry. *Pharmacogenomics* 11(4):559-71
2. Pratt V.M., Cavallari, L.H., et al. (2019) Recommendations for clinical CYP2C9 genotyping allele selection. *J Mol Diagn* 21(5):746-755
3. Johnson J.A., Caudle K.E., et al. (2017) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. *Clin Pharmacol Ther* 102(3):397–404
4. Hamberg, A.K., Wadelius, M., et al. (2014) Characterizing variability in warfarin dose requirements in children using modelling and simulation. *Br J Clin Pharmacol* 78:158–169
5. Shaw, K., Amstutz, U., et al. (2014). VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. *Pediatr Blood Cancer* 61(6):1055-62